Amarin Unveils New REDUCE-IT Analyses Highlighting VASCEPA Efficacy at AHA 2025
Amarin Corporation plc will present new analyses from the REDUCE-IT study at the American Heart Association’s Scientific Sessions 2025, focusing on the efficacy of Icosapent Ethyl (VASCEPA®/VAZKEPA®) for cardiovascular risk reduction. The presentations will include data on outcomes related to baseline aspirin use and mechanistic studies on the properties of Eicosapentaenoic Acid (EPA). Results will be shared during abstract and poster sessions at the conference, scheduled for November 7-10 in New Orleans, Louisiana.
Amarin Corporation plc announced it will present new analyses at the American Heart Association’s Scientific Sessions 2025, scheduled for November 7-10 in New Orleans, Louisiana. The presentations will include new data from the REDUCE-IT study, evaluating the efficacy of Icosapent Ethyl (VASCEPA®/VAZKEPA®) for cardiovascular risk reduction, including outcomes based on baseline aspirin use. Additional mechanistic studies will address the anti-oxidant, anti-inflammatory, and endothelial-protective properties of Eicosapentaenoic Acid (EPA), particularly its effects on lipoprotein(a) oxidation and endothelial cell stress responses. The results are scheduled to be presented during designated abstract and poster sessions at the upcoming conference. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amarin Corporation plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9565928-en) on November 03, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
